Silexion's SIL204 Shows Multi-Mechanism Immune Sensitization in KRAS Cancers, Phase 2/3 Trial Underway
SLXN is trading near its 52-week low of $1.5 (7.3% above the low) on light trading volume (0.1× avg).
Summary
Silexion reported new preclinical data for its lead candidate SIL204, demonstrating statistically significant upregulation of the immune death receptor FAS and downregulation of the immune checkpoint HLA-G across multiple KRAS-mutant cancer cell lines. These findings build on previously reported MHC-I upregulation, suggesting a coordinated immune-sensitizing effect that could enhance combination with checkpoint inhibitors. The company also disclosed that it has advanced SIL204 into Phase 2/3 clinical evaluation, with the first trial site initiated at Tel Aviv Sourasky Medical Center in late July 2026. This marks a concrete step toward clinical validation, though the company remains early-stage with a market cap around $2 million and a recent history of going concern warnings and shareholder disputes. The data will be presented at a cancer symposium, which could attract partnership interest, but the immediate financial impact is limited given the company's precarious cash position.
At the time of this announcement, SLXN was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $1.50 to $111.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.